{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:10:33Z","timestamp":1791180633199,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001543","name":"Children's Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Thomas Willson and Lenore Williams McKnew Endowment fund"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.cancergen.2014.09.002","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T00:13:35Z","timestamp":1410826415000},"page":"403-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor"],"prefix":"10.1016","volume":"207","author":[{"given":"Yafang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunbiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2014.09.002_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/28212","article-title":"Truncating mutations of hSNF5\/INI1 in aggressive paediatric cancer","volume":"394","author":"Versteege","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2014.09.002_bib2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1086\/302639","article-title":"Constitutional mutations of the hSNF5\/INI1 gene predispose to a variety of cancers","volume":"65","author":"S\u00e9venet","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cancergen.2014.09.002_bib3","first-page":"3461","article-title":"Alterations of the hSNF5\/INI1 gene in central nervous system atypical teratoid\/rhabdoid tumors and renal and extrarenal rhabdoid tumors","volume":"8","author":"Biegel","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2014.09.002_bib4","doi-asserted-by":"crossref","first-page":"13796","DOI":"10.1073\/pnas.250492697","article-title":"Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice","volume":"97","author":"Roberts","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cancergen.2014.09.002_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4161\/cbt.8.5.8019","article-title":"The role of SMARCB1\/INI1 in development of rhabdoid tumor","volume":"8","author":"Roberts","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.cancergen.2014.09.002_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/pbc.22831","article-title":"Spectrum of SMARCB1\/INI1 mutations in familial and sporadic rhabdoid tumors","volume":"56","author":"Eaton","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cancergen.2014.09.002_bib7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/513207","article-title":"Germline mutation of INI1\/SMARCB1 in familial schwannomatosis","volume":"80","author":"Hulsebos","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cancergen.2014.09.002_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1399-0004.2008.01060.x","article-title":"Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis","volume":"74","author":"Boyd","year":"2008","journal-title":"Clin Genet"},{"key":"10.1016\/j.cancergen.2014.09.002_bib9","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1200\/JCO.2004.00.8110","article-title":"Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor","volume":"23","author":"Tomlinson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2014.09.002_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/pbc.22922","article-title":"Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group","volume":"56","author":"van den Heuvel-Eibrink","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cancergen.2014.09.002_bib11","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1200\/JCO.2004.07.073","article-title":"Central nervous system atypical teratoid\/rhabdoid tumor: results of therapy in children enrolled in a registry","volume":"22","author":"Hilden","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2014.09.002_bib12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2005.05.187","article-title":"Atypical teratoid\/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy","volume":"23","author":"Tekautz","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cancergen.2014.09.002_bib13","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1126\/science.7605428","article-title":"Specific association of human telomerase activity with immortal cells and cancer","volume":"266","author":"Kim","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.cancergen.2014.09.002_bib14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0959-8049(97)00062-2","article-title":"A\u00a0survey of telomerase activity in human cancer","volume":"33","author":"Shay","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cancergen.2014.09.002_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.cancergen.2014.09.002_bib16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/sj.onc.1205064","article-title":"Oligonucleotide N3\u2032-->P5\u2032 phosphoramidates as efficient telomerase inhibitors","volume":"21","author":"Herbert","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.cancergen.2014.09.002_bib17","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1158\/0008-5472.CAN-05-1215","article-title":"In\u00a0vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor","volume":"65","author":"Dikmen","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2014.09.002_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10549-005-9043-5","article-title":"Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer","volume":"96","author":"Gellert","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cancergen.2014.09.002_bib19","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/leu.2008.81","article-title":"Telomerase inhibitor GRN163L inhibits myeloma cell growth in\u00a0vitro and in\u00a0vivo","volume":"22","author":"Shammas","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2014.09.002_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1078-0432.CCR-09-2850","article-title":"The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth","volume":"16","author":"Marian","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2014.09.002_bib21","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1158\/1078-0432.CCR-13-1117","article-title":"A\u00a0phase I trial of imetelstat in children with refractory or recurrent solid tumors: a\u00a0Children's Oncology Group Phase I Consortium Study (ADVL1112)","volume":"19","author":"Thompson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergen.2014.09.002_bib22","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1158\/0008-5472.CAN-04-0453","article-title":"Disappearance of the telomere dysfunction-induced stress response in fully senescent cells","volume":"64","author":"Bakkenist","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2014.09.002_bib23","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/30.10.e47","article-title":"Telomere measurement by quantitative PCR","volume":"30","author":"Cawthon","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cancergen.2014.09.002_bib24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pbc.21078","article-title":"The pediatric preclinical testing program: description of models and early testing results","volume":"49","author":"Houghton","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cancergen.2014.09.002_bib25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature02118","article-title":"A\u00a0DNA damage checkpoint response in telomere-initiated senescence","volume":"426","author":"d'Adda di Fagagna","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.cancergen.2014.09.002_bib26","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0960-9822(03)00542-6","article-title":"DNA damage foci at dysfunctional telomeres","volume":"13","author":"Takai","year":"2003","journal-title":"Curr Biol"},{"key":"10.1016\/j.cancergen.2014.09.002_bib27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/0008-5472.CAN-06-2306","article-title":"Antiadhesive effects of GRN163L\u2013an oligonucleotide N3\u2032->P5\u2032 thio-phosphoramidate targeting telomerase","volume":"67","author":"Jackson","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2014.09.002_bib28","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3892\/ijo.2013.1865","article-title":"Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton","volume":"42","author":"Mender","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.cancergen.2014.09.002_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0092-8674(01)00504-9","article-title":"The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability","volume":"107","author":"Hemann","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.cancergen.2014.09.002_bib30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ng1127","article-title":"Erosion of the telomeric single-strand overhang at replicative senescence","volume":"33","author":"Stewart","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.cancergen.2014.09.002_bib31","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1128\/MCB.00658-08","article-title":"Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability","volume":"28","author":"McKenna","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cancergen.2014.09.002_bib32","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1038\/sj.emboj.7601291","article-title":"Mammalian SWI\/SNF complexes facilitate DNA double-strand break repair by promoting gamma-H2AX induction","volume":"25","author":"Park","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.cancergen.2014.09.002_bib33","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1128\/MCB.26.7.2661-2674.2006","article-title":"Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5\/Ini1 subunit of the SWI\/SNF chromatin remodeling complex","volume":"26","author":"Klochendler-Yeivin","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cancergen.2014.09.002_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.dnarep.2008.08.011","article-title":"Mammalian SWI\/SNF chromatin remodeling complexes are required to prevent apoptosis after DNA damage","volume":"8","author":"Park","year":"2009","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.cancergen.2014.09.002_bib35","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1172\/JCI64400","article-title":"A\u00a0remarkably simple genome underlies highly malignant pediatric rhabdoid cancers","volume":"122","author":"Lee","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cancergen.2014.09.002_bib36","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/sj.onc.1205706","article-title":"Re-expression of hSNF5\/INI1\/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB","volume":"21","author":"Betz","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.cancergen.2014.09.002_bib37","doi-asserted-by":"crossref","first-page":"10192","DOI":"10.1158\/0008-5472.CAN-05-1896","article-title":"Loss of the hSNF5 gene concomitantly inactivates p21CIP\/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells","volume":"65","author":"Chai","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2014.09.002_bib38","doi-asserted-by":"crossref","first-page":"17745","DOI":"10.1073\/pnas.0509014102","article-title":"Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation","volume":"102","author":"Isakoff","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cancergen.2014.09.002_bib39","doi-asserted-by":"crossref","first-page":"12129","DOI":"10.1073\/pnas.0505300102","article-title":"Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss","volume":"102","author":"Tsikitis","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cancergen.2014.09.002_bib40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/sj.onc.1209112","article-title":"Targeting cyclin D1, a downstream effector of INI1\/hSNF5, in rhabdoid tumors","volume":"25","author":"Alarcon-Vargas","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.cancergen.2014.09.002_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbrc.2011.08.047","article-title":"Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression","volume":"413","author":"Katsumi","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cancergen.2014.09.002_bib42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1073\/pnas.0913297108","article-title":"Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1","volume":"108","author":"Smith","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cancergen.2014.09.002_bib43","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/0008-5472.CAN-10-2167","article-title":"Aurora A is a repressed effector target of the chromatin remodeling protein INI1\/hSNF5 required for rhabdoid tumor cell survival","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.cancergen.2014.09.002_bib44","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.192.11.1625","article-title":"Short telomeres result in organismal hypersensitivity to ionizing radiation in mammals","volume":"192","author":"Goytisolo","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cancergen.2014.09.002_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/79232","article-title":"Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation","volume":"26","author":"Wong","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.cancergen.2014.09.002_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yexcr.2004.04.004","article-title":"Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress","volume":"298","author":"Rubio","year":"2004","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.cancergen.2014.09.002_bib47","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1940-6207.CAPR-11-0069","article-title":"Telomere shortening alters the kinetics of the DNA damage response after ionizing radiation in human cells","volume":"4","author":"Drissi","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.cancergen.2014.09.002_bib48","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1101\/gad.13.7.817","article-title":"Functional requirement of p23 and Hsp90 in telomerase complexes","volume":"13","author":"Holt","year":"1999","journal-title":"Genes Dev"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776214001781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776214001781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:40:42Z","timestamp":1761896442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776214001781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S2210776214001781"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2014.09.002","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2014.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}